Incannex Healthcare vs NeOnc Technologies
IXHL and NTHI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IXHL and NTHI compare
NeOnc Technologies is the larger company, worth 5.1 times as much as Incannex Healthcare ($112M against $21.8M).
Incannex Healthcare scores higher on the StockData Score (7 against 0 for NeOnc Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IXHL | NTHI |
|---|---|---|
| Size and price | ||
| Market cap | $21.8M | $112M |
| Share price | $1.74 | $4.33 |
| Change, 1 year | −83.5% | −52.3% |
| Beta (5Y) | 2.40 | 2.81 |
| Employees | 12 | 5 |
| StockData Score | ||
| Total score | 7 (better) | 0 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.3× | – |
| FCF yield | −14.6% | – |
| Profitability | ||
| Return on equity | −20.7% | – |
| Return on invested capital | −1945% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −15.7× |
| Current ratio | 67.79 (better) | 0.38 |
| Altman Z-score | −0.22 (better) | −34.30 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −42.2% | – |
| Shareholder yield | −42.2% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 3.6% | 12.2% |
| Held by insiders | – | 60.1% |
| Insider net buying, 12 months | – | $2.0M |
| Short interest, % of float | – | 8.9% |
Go deeper
- IXHL stock overview
- IXHL income statement
- IXHL valuation and score
- NTHI stock overview
- NTHI income statement
- NTHI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.